Key Highlights

  • Sales rose 6.8% to US$2,140.2 million, and adjusted EBIT rose 14.1% to US$321.9 million.
  • Operating cash flow rose to US$270.1 million from US$105.4 million, and net Debt fell to US$510.6 million.
  • The full-year Dividend was 68.1 US cents, up 35.7%, at a 45% payout ratio.
  • FY27 adjusted EPS guidance of 158 to 170 US cents implies growth of roughly 7% to 14%.

What changes when a protective-equipment maker grows sales, lifts margins and generates far more cash in the same year? For Ansell Limited (ASX:ANN), the FY26 result presented on 24 August 2026 points to a Business that has absorbed US tariffs and cost inflation, moved Leverage lower and guided to further Earnings growth.

The central development: higher margins and more encouraging cash conversion

Sales were US$2,140.2 million, up 6.8%. Adjusted EBIT was US$321.9 million, up 14.1%, and the adjusted EBIT Margin was 15.0%, up 90 basis points. Adjusted Earnings Per Share were 148.6 US cents, up 18.5% on an organic constant-currency basis.

Cash was a standout. Net debt fell to US$510.6 million from US$570.2 million, and net debt to adjusted EBITDA improved to 1.3 times from 1.6 times. Liquidity was US$752 million, including undrawn facilities, and the Credit rating was Moody's Baa2.

Business and Revenue drivers

Ansell has two divisions. Industrial (hand and body protection for factories, construction and similar sites) reported sales of US$947.3 million, up 5.4%, and adjusted EBIT of US$170.6 million at an 18.0% margin. Healthcare (surgical and examination gloves, plus cleanroom and life-science products) reported sales of US$1,192.9 million, up 8.0%, with adjusted EBIT of US$170.7 million at a 14.3% margin, up from 12.8%.

Healthcare's second half is notable: sales growth was 12.3% in the second half against 1.1% in the first, and the cleanroom business grew 10.0% (17.2% in the second half).

A reconciliation point: the two divisional EBIT figures sum to US$341.3 million, above the US$321.9 million group number.

Cost, tariffs and efficiency

Management said that US Tariff effects were offset by sourcing optimisation and price increases, and that Middle East crisis cost Inflation was offset through supply-chain resilience and Brand pricing power. Ansell is also seeking refunds on tariffs paid before a US Supreme Court ruling in February 2026, and about US$12 million had been received by July.

An efficiency programme referred to as APIP delivered US$50 million of recurring pre-tax savings in FY26, and an ERP rollout in North America is planned for FY27. Systems projects can disrupt operations, so the rollout is a risk as well as a cost saving.

Capital returns

The full-year dividend was 68.1 US cents, up 35.7%, at a 45% payout ratio, with a final dividend of 41.5 US cents. Ansell spent about US$118 million on its on-market buyback under an existing US$200 million programme, which continues. Capital use in the year included about US$78.8 million of dividends and US$118.4 million of buybacks, alongside a net debt reduction of about US$60 million.

FY27 guidance

Ansell guided to FY27 adjusted EPS of 158 to 170 US cents, before significant items and excluding buyback effects. That implies growth of roughly 7% to 14% on 148.6 cents. The guidance includes an expected foreign-exchange benefit of about US$9 million, mainly from lower hedge-contract losses, and Capital Expenditure of US$45 million to US$55 million. Guidance is a company forecast and can be revised, especially if tariffs, input costs or Demand change.

Sector and competitive position

Ansell competes with large glove and protective-equipment manufacturers, many in Asia, as well as brand owners in cleanroom and surgical categories. Its argument, as management presents it, rests on brand strength, innovation, supply-chain Diversification and pricing power. The business remains exposed to healthcare demand, the cost of raw materials such as nitrile and natural rubber, and shipping and tariff changes.

Material risks

Tariffs and trade policy. Refunds are uncertain and new tariffs could emerge.

Input and freight costs. Middle East disruption or raw-material moves could outpace pricing.

Healthcare demand variability. The H1/H2 split in Healthcare growth shows how uneven demand can be.

Integration. The KBU portfolio must be integrated and its growth sustained.

System rollout. The North American ERP programme could disrupt operations.

Currency. Ansell reports in US dollars while listed in Australia, so exchange rates affect Australian-dollar returns.

What to watch next

Investors may look to the first-half FY27 result for evidence that second-half Healthcare momentum has continued, for progress on tariff refunds, and for the AGM trading update.

Ansell's result is encouraging on margins and cash. Even so, the guidance is a range, the second-half Healthcare strength needs to persist, and the sensitivities above are what will decide where within that range the outcome falls.